Telomir Pharmaceuticals, Inc. SEC filings TELO

Telomir Pharmaceuticals, Inc. has 149 filings in SEC EDGAR's recent list, going back to Apr 3, 2023. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 6, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.

Telomir Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
424B3 Prospectus Nov 5, 2026 —
S-3 Shelf registration Oct 27, 2026 —
S-3 Shelf registration Feb 14, 2025 —
424B4 Prospectus Feb 12, 2024 —
424B1 Filing Feb 12, 2024 —
S-1/A Amended registration statement Jan 3, 2024 —
S-1/A Amended registration statement Dec 19, 2023 —
S-1/A Amended registration statement Dec 14, 2023 —
S-1 Registration statement Nov 14, 2023 —

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TELO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
FL
Headquarters
Miami, FL
SEC filer status
, Emerging growth company
SEC CIK
1971532

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.